Efficacy and safety of oral deferasirox treatment in the posttransplant period for patients who have undergone allogeneic hematopoietic stem cell transplantation (alloHSCT)

Iron overload is considered to be associated with various complications in patients who undergo both allogeneic (allo) and autologous hematopoietic stem cell transplantation (HSCT). A total of 23 alloHSCT recipients who started deferasirox treatment due to hyperferritinemia (ferritin ≥1,000 ng/mL) w...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2012-05, Vol.91 (5), p.743-749
Main Authors: Sivgin, Serdar, Eser, Bulent, Bahcebasi, Sami, Kaynar, Leylagul, Kurnaz, Fatih, Uzer, Elmas, Pala, Cigdem, Deniz, Kemal, Ozturk, Ahmet, Cetin, Mustafa, Unal, Ali
Format: Article
Language:English
Subjects:
Adolescent
Adult
Benzoates - adverse effects
Benzoates - therapeutic use
Female
Hematology
Hematopoietic Stem Cell Transplantation
Humans
Iron Chelating Agents - adverse effects
Iron Chelating Agents - therapeutic use
Iron Overload - drug therapy
Iron Overload - etiology
Iron Overload - mortality
Kidney - physiopathology
Leukemia - complications
Leukemia - therapy
Leukemia, Myeloid, Acute - complications
Leukemia, Myeloid, Acute - therapy
Liver - pathology
Liver - physiopathology
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Phlebotomy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications
Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy
Transplantation, Homologous
Triazoles - adverse effects
Triazoles - therapeutic use
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Iron overload is considered to be associated with various complications in patients who undergo both allogeneic (allo) and autologous hematopoietic stem cell transplantation (HSCT). A total of 23 alloHSCT recipients who started deferasirox treatment due to hyperferritinemia (ferritin ≥1,000 ng/mL) were analyzed retrospectively. The demographic characteristics, data about deferasirox treatment, and history of phlebotomy were obtained from the patients’ files. The reduction in posttreatment ferritin levels was found statistically significant compared with pretreatment ferritin levels in both def+phlebotomy and def+nonphlebotomy groups ( p  = 0.025 and 0.017, respectively). The liver enzymes, especially ALT and bilirubins, were significantly reduced after the treatment ( p  
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-011-1358-1